{"news_desk": "Editorial", "print_page": "26", "section_name": "Opinion", "subsection_name": null, "byline": {"original": "By THE EDITORIAL BOARD", "person": [], "organization": "THE EDITORIAL BOARD"}, "abstract": "Editorial offers conditional praise for FDA's approval of drug Addyi to treat sexual dysfunction in women; questions, however, whether decision was unduly influenced by manufacturer Sprout Pharmaceuticals, which took part in campaign focusing on gender-bias as possible reason no libido-enhancing drug has ever been approved for women; cautions women and their doctors to talk frankly and work together to mitigate drug's potential risks. ", "type_of_material": "Editorial", "word_count": "455", "lead_paragraph": "Women who can benefit from the drug need to be aware of the risks and how to mitigate them.", "pub_date": "2015-08-21T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "\u2018Little Pink Pill\u2019 for Women Comes With Risks", "content_kicker": "Editorial", "print_headline": "A Libido Pill and Its Side Effects  ", "kicker": "Editorial"}, "snippet": "Women who can benefit from the drug need to be aware of the risks and how to mitigate them.", "multimedia": [{"height": 126, "url": "images/2015/08/21/opinion/21fri3web/21fri3web-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/08/21/opinion/21fri3web/21fri3web-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 350, "url": "images/2015/08/21/opinion/21fri3web/21fri3web-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "350", "xlarge": "images/2015/08/21/opinion/21fri3web/21fri3web-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/08/21/opinion/21fri3web/21fri3web-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/08/21/opinion/21fri3web/21fri3web-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/08/21/opinion/little-pink-pill-for-women-comes-with-risks.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Editorials", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Addyi (Drug)", "name": "subject"}, {"rank": "3", "is_major": "Y", "value": "Food and Drug Administration", "name": "organizations"}, {"rank": "4", "is_major": "Y", "value": "Sex", "name": "subject"}, {"rank": "5", "is_major": "Y", "value": "Women and Girls", "name": "subject"}, {"rank": "6", "is_major": "Y", "value": "Sprout Pharmaceuticals Inc", "name": "organizations"}, {"rank": "7", "is_major": "N", "value": "Valeant Pharmaceuticals International Inc", "name": "organizations"}, {"rank": "8", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}], "blog": [], "_id": "55d6d16338f0d81d6b2effbb", "source": "The New York Times"}